Axel Prof. Dr. Ullrich

Axel Prof. Dr. Ullrich's AcademicInfluence.com Rankings

Biology

#1821

World Rank

#2958

Historical Rank

Molecular Biology

#103

World Rank

#106

Historical Rank

Genetics

#106

World Rank

#142

Historical Rank

biology Degrees

Download Badge

Biology

Axel Prof. Dr. Ullrich's Degrees

Bachelors Biology University of California, Berkeley
PhD Molecular Biology Stanford University
Doctorate Oncology Harvard University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Axel Prof. Dr. Ullrich Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Axel Prof. Dr. Ullrich's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. (1987) (11735)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. (1989) (6994)
Signal transduction by receptors with tyrosine kinase activity (1990) (5143)
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells (1984) (2426)
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences (1984) (2385)
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis (1993) (2030)
Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes (1985) (1886)
Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. (1986) (1745)
Growth factor receptor tyrosine kinases. (1988) (1648)
Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. (1987) (1557)
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors (1996) (1534)
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin (1985) (1523)
Growth factor signaling by receptor tyrosine kinases (1992) (1395)
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant (1994) (1290)
The discovery of receptor tyrosine kinases: targets for cancer therapy (2004) (1181)
EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF (1999) (1149)
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. (1999) (1099)
Paul Ehrlich's magic bullet concept: 100 years of progress (2008) (1051)
Rat insulin genes: construction of plasmids containing the coding sequences. (1977) (1026)
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors (1986) (1004)
Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. (1986) (933)
Synthesis of Messenger RNAs for Transforming Growth Factors α and β and the Epidermal Growth Factor Receptor by Human Tumors (1987) (916)
Protein kinase C (1991) (793)
Targeting polo-like kinase 1 for cancer therapy (2006) (790)
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor (1989) (752)
The complete primary structure of protein kinase C--the major phorbol ester receptor. (1986) (749)
The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. (2001) (701)
Signal characteristics of G protein‐transactivated EGF receptor (1997) (701)
A family of proteins that inhibit signalling through tyrosine kinase receptors (1997) (660)
The SH2/SH3 domain‐containing protein GRB2 interacts with tyrosine‐phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. (1993) (643)
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. (1987) (638)
Epidermal growth factor receptors: critical mediators of multiple receptor pathways. (1999) (619)
Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms (2004) (618)
Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement (2003) (616)
Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells (1987) (604)
HER-2/neu oncogene protein and prognosis in breast cancer. (1989) (560)
A fusion protein required for vesicle-mediated transport in both mammalian cells and yeast (1989) (533)
Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. (1993) (532)
Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. (1993) (526)
Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. (1996) (518)
Smart drugs: tyrosine kinase inhibitors in cancer therapy. (2002) (510)
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. (2000) (505)
Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission (2001) (490)
EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor (1994) (487)
Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. (1987) (474)
Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor (1983) (451)
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. (1996) (445)
Construction and fine mapping of recombinant plasmids containing the rrnB ribosomal RNA operon of E. coli. (1981) (444)
Kinase activity controls the sorting of the epidermal growth factor receptor within the multivesicular body (1990) (442)
Human leukocyte interferon produced by E. coli is biologically active (1980) (435)
The structure of eight distinct cloned human leukocyte interferon cDNAs (1981) (431)
Human β-nerve growth factor gene sequence highly homologous to that of mouse (1983) (431)
EGFR signal transactivation in cancer cells. (2003) (426)
Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus (1986) (419)
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. (2015) (417)
Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. (1990) (416)
Down-regulation of protein kinase C is due to an increased rate of degradation. (1987) (412)
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. (1995) (411)
Receptor tyrosine kinase signalling as a target for cancer intervention strategies. (2001) (393)
Flk-1 expression defines a population of early embryonic hematopoietic precursors. (1997) (379)
The EGF receptor as central transducer of heterologous signalling systems. (1999) (377)
TACE cleavage of proamphiregulin regulates GPCR‐induced proliferation and motility of cancer cells (2003) (362)
ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. (1996) (359)
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells (2014) (347)
Interplay between mycobacteria and host signalling pathways (2004) (346)
Unified Nomenclature for Eph Family Receptors and Their Ligands, the Ephrins (1997) (343)
Functionally distinct insulin receptors generated by tissue‐specific alternative splicing. (1990) (341)
Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity (1988) (339)
Strategies to overcome resistance to targeted protein kinase inhibitors (2004) (336)
Flk-1 as a target for tumor growth inhibition. (1996) (335)
PTP‐SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal‐regulated kinases ERK1 and ERK2 by association through a kinase interaction motif (1998) (331)
Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. (1986) (327)
A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. (1988) (318)
Phosphorylation and Free Pool of β-Catenin Are Regulated by Tyrosine Kinases and Tyrosine Phosphatases during Epithelial Cell Migration* (1999) (306)
The c‐sis gene encodes a precursor of the B chain of platelet‐derived growth factor. (1984) (303)
Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLC gamma. (1994) (301)
Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors (1992) (301)
Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. (1999) (298)
Molecular targets for breast cancer therapy and prevention (2001) (296)
Transforming potential of the c-fms proto-oncogene (CSF-1 receptor) (1987) (293)
Identification of Trk binding sites for SHC and phosphatidylinositol 3'-kinase and formation of a multimeric signaling complex. (1993) (290)
Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion (2004) (290)
Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor (2004) (284)
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. (2002) (278)
SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high‐affinity binding site for SH2 domains of phospholipase C gamma. (1992) (276)
Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme (2008) (266)
Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. (1995) (264)
Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor (1984) (257)
Insulin-like growth factor II precursor gene organization in relation to insulin gene family (1984) (257)
Bidirectional Negative Regulation of Human T and Dendritic Cells by CD47 and Its Cognate Receptor Signal-Regulator Protein-α: Down-Regulation of IL-12 Responsiveness and Inhibition of Dendritic Cell Activation1 (2001) (256)
Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. (1995) (255)
Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation (2006) (254)
Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. (2006) (254)
Receptor tyrosine kinases as targets for anticancer drugs. (2002) (250)
Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues (1990) (248)
The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC‐gamma. (1990) (246)
Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. (1996) (237)
Structural basis for Gas6–Axl signalling (2006) (237)
Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. (2002) (228)
Progression of human cutaneous melanoma is associated with loss of expression of c‐kit proto‐oncogene receptor (1992) (223)
Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1 (2006) (222)
A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization (1991) (219)
Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. (1994) (217)
Three additional inositol 1,4,5-trisphosphate receptors: molecular cloning and differential localization in brain and peripheral tissues. (1992) (216)
Critical Role of Calcium- dependent Epidermal Growth Factor Receptor Transactivation in PC12 Cell Membrane Depolarization and Bradykinin Signaling* (1997) (216)
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. (2008) (215)
Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. (1992) (215)
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. (1991) (214)
AXL is a potential target for therapeutic intervention in breast cancer progression. (2008) (214)
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic (1991) (209)
Annexin I is phosphorylated in the multivesicular body during the processing of the epidermal growth factor receptor (1993) (206)
Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. (1988) (203)
The avian beta-adrenergic receptor: primary structure and membrane topology. (1986) (203)
Association of Human Protein-tyrosine Phosphatase κ with Members of the Armadillo Family* (1996) (202)
ErbB-3 predicts survival in ovarian cancer. (2006) (199)
The secreted tumor-associated antigen 90K is a potent immune stimulator. (1994) (196)
Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. (1990) (193)
Molecular analysis of signal transduction by growth factors. (1988) (193)
Differential signalling potential of insulin‐ and IGF‐1‐receptor cytoplasmic domains. (1989) (191)
Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. (2001) (190)
Distinct ADAM Metalloproteinases Regulate G Protein-coupled Receptor-induced Cell Proliferation and Survival* (2004) (190)
Inositol 1,4,5-trisphosphate receptors: distinct neuronal and nonneuronal forms derived by alternative splicing differ in phosphorylation. (1991) (184)
Functional analysis of the ligand binding site of EGF‐receptor utilizing chimeric chicken/human receptor molecules. (1989) (181)
Tyrosine 785 is a major determinant of Trk‐‐substrate interaction. (1993) (181)
Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells. (1986) (179)
Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. (1991) (179)
Primary structure and mRNA localization of protein F1, a growth‐related protein kinase C substrate associated with synaptic plasticity. (1987) (175)
SAF-B protein couples transcription and pre-mRNA splicing to SAR/MAR elements. (1998) (175)
SH2 domains exhibit high-affinity binding to tyrosine-phosphorylated peptides yet also exhibit rapid dissociation and exchange (1993) (173)
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. (1987) (172)
The SH2 and SH3 domain-containing Nck protein is oncogenic and a common target for phosphorylation by different surface receptors (1992) (171)
Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. (2007) (171)
Cloning and Characterization of Secretory Tyrosine Phosphatases of Mycobacterium tuberculosis (2000) (171)
Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. (1991) (170)
A point mutation at the ATP‐binding site of the EGF‐receptor abolishes signal transduction. (1988) (170)
Class II Phosphoinositide 3-Kinases Are Downstream Targets of Activated Polypeptide Growth Factor Receptors (2000) (169)
Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. (1992) (166)
High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains. (1992) (165)
All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. (1989) (164)
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis (2006) (163)
Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor - convergence point for signal integration and diversification (2000) (163)
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. (1999) (160)
A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis (1987) (160)
Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha (1988) (159)
Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site (1997) (159)
Cellular Redistribution of Protein Tyrosine Phosphatases LAR and PTPσ by Inducible Proteolytic Processing (1997) (159)
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. (2009) (158)
Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. (1998) (157)
Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family. (1995) (155)
Molecular cloning and expression of a G25K cDNA, the human homolog of the yeast cell cycle gene CDC42 (1990) (154)
Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene. (1987) (153)
Association of SH2 Domain Protein Tyrosine Phosphatases with the Epidermal Growth Factor Receptor in Human Tumor Cells (1995) (151)
Oxidative and Osmotic Stress Signaling in Tumor Cells Is Mediated by ADAM Proteases and Heparin-Binding Epidermal Growth Factor (2004) (149)
Mig-6 Is a Negative Regulator of the Epidermal Growth Factor Receptor Signal (2001) (149)
HER3 Is a Determinant for Poor Prognosis in Melanoma (2008) (148)
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. (2004) (148)
Mammalian SH2-Containing Protein Tyrosine Phosphatases (1996) (146)
Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression (1996) (143)
Selective Down-regulation of the Insulin Receptor Signal by Protein-tyrosine Phosphatases α and ε (*) (1995) (143)
PTP1D is a positive regulator of the prolactin signal leading to beta‐casein promoter activation. (1996) (143)
Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. (1989) (143)
Differential activities of protein tyrosine phosphatases in intact cells. (1993) (142)
Identification of SRPK1 and SRPK2 as the Major Cellular Protein Kinases Phosphorylating Hepatitis B Virus Core Protein (2002) (142)
Tyrosine kinase activity is essential for the association of phospholipase C-gamma with the epidermal growth factor receptor (1990) (141)
Genetic variation in the human insulin gene. (1980) (141)
A mutation in the insulin receptor gene that impairs transport of the receptor to the plasma membrane and causes insulin‐resistant diabetes. (1989) (140)
Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants (1992) (137)
Dynamin binds to SH3 domains of phospholipase C gamma and GRB-2. (1994) (137)
Effect of phospholipase C-gamma overexpression on PDGF-induced second messengers and mitogenesis. (1990) (136)
Cell type‐specific activation of mitogen‐activated protein kinases by CpG‐DNA controls interleukin‐12 release from antigen‐presenting cells (1999) (136)
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. (1997) (135)
Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. (1988) (135)
Novel mechanisms of RTK signal generation. (1997) (133)
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. (2006) (133)
Shc Binding to Nerve Growth Factor Receptor Is Mediated by the Phosphotyrosine Interaction Domain (*) (1995) (132)
High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses (1990) (131)
Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. (1997) (130)
Characterization and comparison of four serine- and arginine-rich (SR) protein kinases. (1997) (130)
Characterization of KIF1C, a New Kinesin-like Protein Involved in Vesicle Transport from the Golgi Apparatus to the Endoplasmic Reticulum* (1998) (128)
Mutations in the cytoplasmic domain of EGF receptor affect EGF binding and receptor internalization. (1986) (128)
Isolation of the human insulin‐like growth factor I gene using a single synthetic DNA probe. (1984) (126)
Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors. (1991) (126)
Topology of signal recognition particle receptor in endoplasmic reticulum membrane (1985) (125)
Mitochondrial AKAP121 Binds and Targets Protein Tyrosine Phosphatase D1, a Novel Positive Regulator of src Signaling (2004) (124)
HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. (1989) (122)
Roles of insulinlike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells (1992) (121)
Breast cancer is associated with loss of the c‐kit oncogene product (1992) (121)
Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF. (2002) (120)
The Unique C-terminal Tail of the Mitogen-activated Protein Kinase ERK5 Regulates Its Activation and Nuclear Shuttling* (2005) (120)
Onset of endogenous synthesis of epidermal growth factor in neonatal mice. (1987) (119)
A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor (1986) (119)
Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells (1990) (118)
A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. (1992) (118)
Reactive Oxygen Species Mediate Met Receptor Transactivation by G Protein-coupled Receptors and the Epidermal Growth Factor Receptor in Human Carcinoma Cells* (2004) (118)
Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts. (1988) (118)
Distinct Calcium-dependent Pathways of Epidermal Growth Factor Receptor Transactivation and PYK2 Tyrosine Phosphorylation in PC12 Cells* (1999) (118)
Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling (1988) (114)
A single phosphotyrosine residue of the prolactin receptor is responsible for activation of gene transcription. (1995) (114)
Investigation of Protein-tyrosine Phosphatase 1B Function by Quantitative Proteomics*S (2008) (114)
Receptor-mediated internalization of insulin requires a 12-amino acid sequence in the juxtamembrane region of the insulin receptor beta-subunit. (1990) (114)
A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. (2002) (112)
Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma (2004) (112)
Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor. (1994) (112)
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. (1991) (112)
Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. (2000) (112)
Properties of a human insulin receptor with a COOH-terminal truncation. II. Truncated receptors have normal kinase activity but are defective in signaling metabolic effects. (1988) (112)
Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors* (2003) (111)
Altered expression of insulin receptor types A and B in the skeletal muscle of non-insulin-dependent diabetes mellitus patients. (1991) (111)
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. (2002) (111)
GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways (2005) (111)
The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. (1987) (109)
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. (1992) (108)
Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer (2011) (108)
The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells. (1991) (108)
Association of signal‐regulatory proteins β with KARAP/DAP‐12 (2000) (108)
Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. (1993) (108)
Structure and nucleotide sequence of a Drosophila melanogaster protein kinase C gene. (1987) (107)
Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts. (1988) (107)
Both SH2 Domains Are Involved in Interaction of SHP-1 with the Epidermal Growth Factor Receptor but Cannot Confer Receptor-directed Activity to SHP-1/SHP-2 Chimera* (1997) (107)
Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. (2005) (106)
Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction. (2009) (105)
Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond. (1994) (105)
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors (2013) (105)
Kinetics of binding, endocytosis, and recycling of EGF receptor mutants (1992) (105)
Motogenic and morphogenic activity of epithelial receptor tyrosine kinases (1996) (105)
Characterization of an endogenous substrate of the insulin receptor in cultured cells. (1987) (104)
Furin-, ADAM 10-, and γ-Secretase-Mediated Cleavage of a Receptor Tyrosine Phosphatase and Regulation of β-Catenin's Transcriptional Activity (2006) (103)
Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localization. (2001) (103)
The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. (1991) (99)
Epidermal growth factor (EGF) stimulates association and kinase activity of Raf-1 with the EGF receptor. (1991) (99)
Protein kinase C isoforms α, δ and θ require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the insulin receptor in human kidney embryonic cells (HEK 293 cells) (1998) (99)
Growth Hormone Regulation of SIRP and SHP-2 Tyrosyl Phosphorylation and Association* (1998) (98)
Phospholipase C‐gamma, a substrate for PDGF receptor kinase, is not phosphorylated on tyrosine during the mitogenic response to CSF‐1. (1989) (97)
Kinetic parameters of the protein tyrosine kinase activity of EGF‐receptor mutants with individually altered autophosphorylation sites. (1988) (97)
Novel signaling pathway suggested by SH3 domain-mediated p95vav/heterogeneous ribonucleoprotein K interaction. (1994) (97)
Lysophosphatidic acid‐regulated mitogenic ERK signaling in androgen‐insensitive prostate cancer PC‐3 cells (2002) (97)
The suitability and application of a GFP-actin fusion protein for long-term imaging of the organization and dynamics of the cytoskeleton in mammalian cells. (1998) (97)
Biological activities of EGF‐receptor mutants with individually altered autophosphorylation sites. (1988) (96)
Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation (2009) (96)
A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. (1996) (95)
Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. (1992) (95)
Beyond Herceptin and Gleevec. (2003) (94)
EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. (1991) (94)
Cell‐type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EGF receptor (1999) (93)
SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin. (1996) (93)
Structure of the N-terminal SH3 domain of GRB2 complexed with a peptide from the guanine nucleotide releasing factor Sos (1994) (92)
SHP-2, SH2-containing protein tyrosine phosphatase-2. (1998) (90)
DNA sequence of two closely linked human leukocyte interferon genes. (1981) (90)
Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor (1997) (90)
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. (2007) (89)
Human beta-nerve growth factor gene sequence highly homologous to that of mouse. (1983) (87)
Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors. (1991) (87)
Tyrosine phosphorylated Par3 regulates epithelial tight junction assembly promoted by EGFR signaling (2006) (86)
The Kinesin-like Motor Protein KIF1C Occurs in Intact Cells as a Dimer and Associates with Proteins of the 14-3-3 Family* (1999) (85)
Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2‐positive cancer cells and cancer stem cells (2012) (83)
p185HER2 signal transduction in breast cancer cells. (1991) (83)
FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients (2006) (82)
Src kinase associates with a member of a distinct subfamily of protein-tyrosine phosphatases containing an ezrin-like domain. (1994) (82)
Alternative splicing increases the diversity of the human protein kinase C family. (1987) (81)
Identification of MMP-15 as an Anti-apoptotic Factor in Cancer Cells* (2005) (81)
Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation (1987) (80)
Nucleotide sequence of a portion of human chromosome 9 containing a leukocyte interferon gene cluster. (1982) (80)
Isolation and developmental expression analysis of Enx-1, a novel mouse Polycomb group gene (1996) (80)
Augmented mitogenesis and impaired metabolic signaling mediated by a truncated insulin receptor. (1989) (79)
Identification of autophosphorylation sites of HER2/neu. (1990) (78)
Properties of a human insulin receptor with a COOH-terminal truncation. I. Insulin binding, autophosphorylation, and endocytosis. (1988) (78)
Cytoplasmic domains determine signal specificity, cellular routing characteristics and influence ligand binding of epidermal growth factor and insulin receptors. (1989) (77)
Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator (2013) (77)
Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584. (1996) (76)
Epidermal Growth Factor Receptor Signal Transactivation (2000) (76)
Adapter Function of Protein-tyrosine Phosphatase 1D in Insulin Receptor/Insulin Receptor Substrate-1 Interaction (*) (1995) (76)
Amplification and Overexpression of the EGF Receptor Gene in Primary Human Glioblastomas (1985) (74)
Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs) (2000) (74)
Insulin receptors with defective tyrosine kinase inhibit normal receptor function at the level of substrate phosphorylation. (1988) (74)
Separate endocytic pathways of kinase-defective and -active EGF receptor mutants expressed in same cells (1990) (73)
Distinct alpha-subunit structures of human insulin receptor A and B variants determine differences in tyrosine kinase activities. (1992) (73)
Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions. (1988) (73)
Identification of alternatively spliced mRNAs encoding variants of MDK1, a novel receptor tyrosine kinase expressed in the murine nervous system. (1995) (73)
Epidermal growth factor: Is the precursor a receptor? (1985) (72)
Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells (2009) (72)
Rapid and Long Term Effects of Protein Kinase C on Receptor Tyrosine Kinase Phosphorylation and Degradation (*) (1995) (72)
Crystal Structure of a C-terminal Fragment of Growth Arrest-specific Protein Gas6 (2002) (72)
Expression of a type I insulin-like growth factor receptor with low affinity for insulin-like growth factor II. (1992) (69)
Mitogen‐inducible gene‐6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma (2010) (69)
Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of GRB2. (1994) (68)
Signal regulation by family conspiracy (2001) (68)
Negative regulation of growth hormone receptor/JAK2 signaling by signal regulatory protein alpha. (2000) (68)
Variation in the sequence and modification state of the human insulin gene flanking regions. (1982) (68)
Multiple restriction fragment length polymorphisms at the insulin receptor locus: a highly informative marker for linkage analysis. (1986) (68)
Nucleotide sequence of part of the gene for human chorionic somatomammotropin: Purification of DNA complementary to predominant mRNA species (1977) (67)
Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. (2005) (67)
Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the her‐2/neu oncogene (1991) (66)
Suppression of tumor growth in vivo by local and systemic 90K level increase. (1995) (66)
Human kidney amiloride-binding protein: cDNA structure and functional expression. (1990) (66)
Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation. (1990) (66)
The Xmrk receptor tyrosine kinase is activated in Xiphophorus malignant melanoma. (1992) (65)
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis (2012) (65)
A Novel Role for Protein Tyrosine Phosphatase SHP1 in Controlling Glial Activation in the Normal and Injured Nervous System (2001) (65)
Release of a phorbol ester-induced mitogenic block by mutation at Thr-654 of the epidermal growth factor receptor (1988) (64)
Overexpression of protein kinase C alpha-subtype in Swiss/3T3 fibroblasts causes loss of both high and low affinity receptor numbers for epidermal growth factor. (1990) (64)
A chimeric, ligand-binding v-erbB/EGF receptor retains transforming potential. (1987) (64)
Cloning, characterization, and differential expression of MDK2 and MDK5, two novel receptor tyrosine kinases of the eck/eph family. (1995) (63)
Peptide-Mediated Inhibition of Neutrophil Transmigration by Blocking CD47 Interactions with Signal Regulatory Protein α1 (2004) (62)
Molecular cloning and sequence analysis of adult chicken β globin cDNA (1979) (62)
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells (2010) (62)
Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells. (1992) (62)
Presence of SH2 domains of phospholipase C gamma 1 enhances substrate phosphorylation by increasing the affinity toward the epidermal growth factor receptor. (1992) (61)
UV‐induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines (2009) (61)
Inhibition of doxorubicin‐induced HER3‐PI3K‐AKT signalling enhances apoptosis of ovarian cancer cells (2012) (61)
Synthesis of growth hormone by bacteria (1978) (60)
Beta-globin locus is linked to the parathyroid hormone (PTH) locus and lies between the insulin and PTH loci in man. (1983) (60)
FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. (2006) (59)
Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy (2009) (58)
Nucleotide sequence of human preproinsulin complementary DNA. (1980) (58)
Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. (1991) (57)
Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site (2015) (57)
Ligand mediated activation of ectopic EGF receptor promotes matrix protein adhesion and lung colonization of rat mammary adenocarcinoma cells. (1995) (56)
Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. (1993) (56)
Characterization of hemopoietic cell populations from human cord blood expressing c-kit. (1993) (56)
Substrate phosphorylation specificity of the human c-kit receptor tyrosine kinase. (1991) (55)
The Cellular Localization of the Murine Serine/Arginine-rich Protein Kinase CLK2 Is Regulated by Serine 141 Autophosphorylation* (1998) (55)
Mammary Gland Remodeling Depends on gp130 Signaling through Stat3 and MAPK* (2004) (54)
Phosphotyrosine-specific Phosphatase PTP-SL Regulates the ERK5 Signaling Pathway* (2002) (54)
Anti‐HER‐3 MAbs inhibit HER‐3‐mediated signaling in breast cancer cell lines resistant to anti‐HER‐2 antibodies (2005) (54)
Pancreatic cancer growth is inhibited by blockade of VEGF-RII. (2003) (54)
Phosphotyrosine residues in the nerve-growth-factor receptor (Trk-A). Their role in the activation of inositolphospholipid metabolism and protein kinase cascades in phaeochromocytoma (PC12) cells. (1995) (53)
The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. (1995) (53)
TaqMan-based quantification of invasive cells in the chick embryo metastasis assay. (2004) (52)
Endothelin‐1 inhibits adipogenesis: Role of phosphorylation of Akt and ERK1/2 (2006) (52)
Interaction of the receptor tyrosine kinase p145c‐kit with the p210bcr/abl kinase in myeloid cells (1996) (52)
PTK 7 Is a Transforming Gene and Prognostic Marker for Breast Cancer and Nodal Metastasis Involvement (2014) (52)
Molecular cloning of a cDNA for the human inositol 1,4,5-trisphosphate receptor type 1, and the identification of a third alternatively spliced variant. (1995) (52)
PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma‐ and melanoma‐cell lines (2012) (51)
Rat insulin genes: construction of plasmids containing the coding sequences. 1977. (1992) (51)
A single nucleotide change in the mouse genome accelerates breast cancer progression. (2010) (51)
Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant (2006) (50)
Cell-free translation of avian sarcoma virus RNA: Suppression of the gag termination codon does not augment synthesis of the joint gag/pol Product (1978) (50)
EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. (2006) (50)
A tumor-derived protein which provides T-cell costimulation through accessory cell activation. (1995) (50)
Signal transduction therapy with rationally designed kinase inhibitors (2006) (50)
Negative Regulation of HER2 Signaling by the PEST-type Protein-tyrosine Phosphatase BDP1* (2004) (49)
The Carboxyl-terminal Tyrosine Residue of Protein-tyrosine Phosphatase α Mediates Association with Focal Adhesion Plaques* (2000) (49)
Signal-regulatory protein a ( SIRP a ) but not SIRP b is involved in T-cell activation , binds to CD 47 with high affinity , and is expressed on immature CD 34 1 CD 38 2 hematopoietic cells (2001) (49)
Intermolecular transphosphorylation between insulin receptors and EGF‐insulin receptor chimerae. (1989) (49)
Protein kinase C isoforms beta 1 and beta 2 inhibit the tyrosine kinase activity of the insulin receptor. (1997) (49)
Insulin inhibits leptin receptor signalling in HEK293 cells at the level of janus kinase-2: a potential mechanism for hyperinsulinaemia-associated leptin resistance (2001) (48)
Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status (2014) (48)
Transforming potentials of epidermal growth factor and nerve growth factor receptors inversely correlate with their phospholipase C gamma affinity and signal activation. (1996) (47)
Protein-tyrosine Phosphatase 1D Modulates Its Own State of Tyrosine Phosphorylation (*) (1995) (46)
Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family. (1996) (46)
Isolation of a cDNA clone coding for the gamma-subunit of mouse nerve growth factor using a high-stringency selection procedure. (1984) (46)
Insulin-induced tyrosine dephosphorylation of paxillin and focal adhesion kinase requires active phosphotyrosine phosphatase 1D. (1996) (46)
Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells (2010) (46)
Ligand-dependent tumor induction in medakafish embryos by a Xmrk receptor tyrosine kinase transgene. (1994) (46)
The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. (1990) (45)
Insulin receptor isotype expression correlates with risk of non-insulin-dependent diabetes. (1993) (45)
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention (2013) (45)
Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer (2014) (45)
A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. (1993) (44)
Defects in human insulin receptor gene expression. (1988) (43)
A mutation in the extracellular domain of the insulin receptor impairs the ability of insulin to stimulate receptor autophosphorylation. (1991) (43)
Abl‐kinase‐sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival (2005) (43)
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo (2016) (42)
Mouse 7S nerve growth factor: complete sequence of a cDNA coding for the alpha-subunit precursor and its relationship to serine proteases. (1984) (42)
90K (Mac‐2 BP) in human milk (1996) (42)
Growth hormone stimulates insulin gene expression in cultured human fetal pancreatic islets. (1988) (41)
The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages. (1996) (41)
PTP-PEST phosphatase variations in human cancer. (2006) (41)
The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src. (2001) (41)
Tyrosine phosphorylation of PYK2 mediates heregulin‐induced glioma invasion: Novel heregulin/HER3‐stimulated signaling pathway in glioma (2005) (41)
Immunoglobulin heavy chain-binding protein binds to misfolded mutant insulin receptors with mutations in the extracellular domain. (1992) (40)
Oncogenic activation of v-kit involves deletion of a putative tyrosine-substrate interaction site. (1995) (40)
The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies (1985) (40)
Dissecting the epidermal growth factor receptor signal transactivation pathway. (2006) (39)
Comparison of EGF receptor sequences as a guide to study the ligand binding site. (1991) (39)
Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation (2006) (38)
Protein kinase C isoforms alpha, delta and theta require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the insulin receptor in human kidney embryonic cells (HEK 293 cells). (1998) (38)
Physical and Functional Interactions between Protein Tyrosine Phosphatase α, PI 3-Kinase, and PKCδ (2001) (37)
Association of signal-regulatory proteins beta with KARAP/DAP-12. (2000) (37)
Structural gene for beta-nerve growth factor not defective in familial dysautonomia. (1984) (36)
Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro. (1995) (36)
The Protein-tyrosine-phosphatase SHP2 is phosphorylated on serine residues 576 and 591 by protein kinase C isoforms alpha, beta 1, beta 2, and eta. (2002) (35)
Differential expression of MAM-subfamily protein tyrosine phosphatases during mouse development (1998) (35)
Effects of growth and insulin treatment on the levels of insulin receptors and their mRNA in Hep G2 cells. (1989) (35)
Distribution of the receptor EphA7 and its ligands in development of the mouse nervous system. (1999) (34)
Protein tyrosine phosphatase PTP20 induces actin cytoskeleton reorganization by dephosphorylating p190 RhoGAP in rat ovarian granulosa cells stimulated with follicle-stimulating hormone. (2003) (34)
Activation of c‐erbB in avian leukosis virus‐induced erythroblastosis leads to the expression of a truncated EGF receptor kinase. (1985) (34)
Cytoplasmic juxtamembrane region of the insulin receptor: a critical role in ATP binding, endogenous substrate phosphorylation, and insulin-stimulated bioeffects in CHO cells. (1991) (34)
Inhibition of Ret Oncogene Activity by the Protein Tyrosine Phosphatase SHP1. (2001) (34)
Differential effects of W mutations on p145c-kit tyrosine kinase activity and substrate interaction. (1992) (33)
The Novel Protein-tyrosine Phosphatase PTP20 Is a Positive Regulator of PC12 Cell Neuronal Differentiation* (1996) (32)
Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer. (1996) (32)
Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases. (1998) (32)
Dominant Negative Form of Signal-regulatory Protein-α (SIRPα/SHPS-1) Inhibits Tumor Necrosis Factor-mediated Apoptosis by Activation of NF-κB* (2002) (32)
Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. (2005) (32)
Extracellular potassium in rat cerebellar cortex during acute and chronic lithium application (1980) (31)
Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells. (2004) (31)
NEK9 depletion induces catastrophic mitosis by impairment of mitotic checkpoint control and spindle dynamics. (2013) (30)
Association between the melanoma-inducing receptor tyrosine kinase Xmrk and src family tyrosine kinases in Xiphophorus. (1995) (30)
Effects of interferons on the expression of the proto‐oncogene her‐2 in human ovarian carcinoma cells (1992) (30)
Epidermal growth factor receptor cytoplasmic domain mutations trigger ligand-independent transformation (1990) (29)
Multisite serine phosphorylation of the insulin and IGF‐I receptors in transfected cells (1991) (29)
Transplantation of the human insulin gene into fertilized mouse eggs. (1982) (29)
The Receptor-like Protein-tyrosine Phosphatase DEP-1 Is Constitutively Associated with a 64-kDa Protein Serine/ Threonine Kinase* (1997) (28)
Autocrine stimulation of the Xmrk receptor tyrosine kinase in Xiphophorus melanoma cells and identification of a source for the physiological ligand. (1994) (28)
Distinct structural specificities for functional coupling of the epidermal growth factor receptor to calcium-signalling versus phospholipase A2 responses. (1991) (28)
Evidence That Two Naturally Occurring Human Insulin Receptor α-Subunit Variants Are Immunologically Distinct (1992) (28)
SHPS-1/SIRP1alpha contributes to interleukin-6 signalling. (2008) (27)
Newly synthesized mammalian cell DNA: studies on the reasons for the increased affinity to nitrocellulose. (1971) (26)
Use of selective tyrosine kinase blockers to monitor growth factor receptor dephosphorylation in intact cells. (1995) (26)
Abrogation of the requirements for added growth factors in 3T3 cells constitutively expressing the p53 and IGF-1 genes. (1988) (26)
The "VH1-like" dual-specificity protein tyrosine phosphatases. (1998) (26)
Segregation of the receptor EphA7 from its tyrosine kinase-negative isoform on neurons in adult mouse brain. (1999) (26)
Expression of epidermal growth-factor receptor correlates with metastatic potential of 13762nf rat mammary adenocarcinoma cells. (1994) (25)
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. (2014) (25)
Characterization of an insulin receptor mutant lacking the subunit processing site. (1990) (25)
Another look at imatinib mesylate. (2006) (24)
Sequence homology of human and mouse beta-NGF subunit genes. (1983) (24)
Domain deletion in the extracellular portion of the EGF-receptor reduces ligand binding and impairs cell surface expression. (1990) (24)
Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma (2002) (24)
Characterization of the PEST family protein tyrosine phosphatase BDP1. (1996) (23)
Retrovirus-mediated transfer of an adenovirus gene encoding an integral membrane protein is sufficient to down regulate the receptor for epidermal growth factor (1990) (23)
Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum. (1991) (23)
SH 2 domains prevent tyrosine dephosphorylation of the EGF receptor : identification of Tyr 992 as the high-affinity binding site for SH 2 domains of phospholipase CT (23)
SU 6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors 1 (2000) (23)
Serine residues 1177/78/82 of the insulin receptor are required for substrate phosphorylation but not autophosphorylation. (2000) (23)
Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients (2017) (22)
Unstable receptors disappear from cell surface during poliovirus infection. (2002) (22)
Selection for transformation and met protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor alpha. (1990) (22)
Phosphatidylinositol 3′‐kinase associates with p145c‐kit as part of a cell type characteristic multimeric signalling complex. (1993) (22)
Stable expression of truncated inositol 1,4,5-trisphosphate receptor subunits in 3T3 fibroblasts. Coordinate signaling changes and differential suppression of cell growth and transformation. (1994) (21)
Epidermal growth factor reduces HER‐2 protein level in human ovarian carcinoma cells (1992) (21)
Ligand-induced activation of epidermal growth factor receptor in intact rat mammary adenocarcinoma cells without detectable receptor phosphorylation. (1992) (21)
Mutant forms of the protein tyrosine phosphatase alpha show differential activities towards intracellular substrates. (1998) (21)
Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor a in NIH 3T3 cells (gene amplification/receptor transmodulation/tumorigenesis) (20)
Mutual Regulation of Protein-tyrosine Phosphatase 20 and Protein-tyrosine Kinase Tec Activities by Tyrosine Phosphorylation and Dephosphorylation* (2004) (20)
GAS6‐expressing and self‐sustaining cancer cells in 3D spheroids activate the PDK‐RSK‐mTOR pathway for survival and drug resistance (2017) (20)
Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B. (2003) (20)
Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications. (2000) (20)
Signal transduction by epidermal growth factor receptor. (1988) (20)
Single-stranded poly(deoxyguanylic acid) associates into double- and triple-stranded structures. (1980) (19)
Translation of mRNA from Calliphora vicina and Drosophila melanogaster larvae into calliphorin and calliphorin-like proteins of Drosophila (1977) (19)
Protein kinases in cellular signal transduction: tyrosine kinase growth factor receptors and protein kinase C. (1986) (19)
Benzylidene‐indolinones are effective as multi‐targeted kinase inhibitor therapeutics against hepatocellular carcinoma (2014) (19)
The 90K tumor-associated antigen and clinical progression in human immunodeficiency virus infection. (1995) (18)
Expression, purification and crystallization of human phosphotyrosine phosphatase 1B. (1994) (18)
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells (2014) (18)
Structural basis for Gas 6 – Axl signalling (2005) (17)
Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors. (2018) (17)
Effect of tumor‐associated mutant E‐cadherin variants with defects in exons 8 or 9 on matrix metalloproteinase 3 (2005) (17)
Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines (2015) (17)
The Ability of Protein Tyrosine Phosphatase SHP-1 to Suppress NFκB Can Be Inhibited by Dominant Negative Mutant of SIRPα (2004) (17)
Role of SH2-containing proteins in cellular signaling by receptor tyrosine kinases. (1992) (16)
Generation of recombinant cytoplasmic domain of epidermal growth factor receptor with intrinsic protein tyrosine kinase activity. (1990) (16)
Studies of the HER-2/neu Proto-Oncogene in Human Breast Cancer (1989) (16)
Development of a lethal mast cell disease in mice reconstituted with bone marrow cells expressing the v-erbB oncogene. (1992) (15)
High-affinity interleukin 2 binding by an oncogenic hybrid interleukin 2-epidermal growth factor receptor molecule. (1987) (15)
Insulin-EGF receptor chimerae mediate tyrosine transphosphorylation and serine/threonine phosphorylation of kinase-deficient EGF receptors. (1991) (15)
Carboxy-terminal truncations of epidermal growth factor (EGF) receptor affect diverse EGF-induced cellular responses. (1991) (15)
Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases (2016) (15)
Stimulation of phospholipase C activity by insulin is mediated by both isotypes of the human insulin receptor. (1991) (14)
Endocytotic uptake, processing, and retroendocytosis of human biosynthetic proinsulin by rat fibroblasts transfected with the human insulin receptor gene. (1988) (14)
Isolation and functional characterization of the human 90K promoter. (1999) (13)
PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs (2014) (13)
Metabolic effects induced by epidermal growth factor (EGF) in cells expressing EGF receptor mutants. (1989) (13)
Prediction oriented QSAR modelling of EGFR inhibition. (2006) (13)
Activation of phosphatidylinositol-3-kinase by insulin is mediated by both A and B human insulin receptor types. (1991) (13)
Hormonal regulation of protein tyrosine kinase activity (1987) (13)
Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. (2013) (13)
HER2/neu: a target for breast cancer therapy. (2000) (13)
Inositol phospho-oligosaccharides from rat fibroblasts and adipocytes stimulate 3-O-methylglucose transport. (1993) (12)
Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKCdelta. (2001) (11)
Structure of human epidermal growth factor receptor and expression of normal and variant mRNAs in epidermoid carcinoma cells (1985) (11)
The ability of protein tyrosine phosphatase SHP-1 to suppress NFkappaB can be inhibited by dominant negative mutant of SIRPalpha. (2004) (11)
The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2. (2003) (11)
Molecular Targets in Cancer Therapy and Their Impact on Cancer Management (2002) (10)
Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men (2011) (10)
[Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma]. (2003) (10)
Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes. (2016) (10)
TheSH2andSH3Domain-Containing NckProtein Is Oncogenic andaCommonTarget forPhosphorylation byDifferent Surface Receptors (1992) (9)
Protein tyrosine phosphatases expression during development of mouse superior colliculus (2009) (9)
Molecular Characterization of a cDNA Encoding Functional Human CLK4 Kinase and Localization to Chromosome 4q35 (2001) (9)
Analysis of the protein kinase activity of moss phytochrome expressed in fibroblast cell culture (2004) (9)
C-terminus or juxtamembrane deletions in the insulin receptor do not affect the glucose-dependent inhibition of the tyrosine kinase activity. (1995) (9)
Inhibition of Dendritic Cell Activation : Down-Regulation of IL-12 Responsiveness α Cognate Receptor Signal-Regulator Protein-T and Dendritic Cells by CD 47 and Its Bidirectional Negative Regulation of Human (2001) (8)
Insulin-like growth factor I receptor cDNA cloning. (1991) (8)
Changes in extracellular potassium and calcium in rat cerebellar cortex related to local inhibition of the sodium pump (1982) (8)
One bead, one chemical compound: use of the selectide process for anticancer drug discovery. (1994) (8)
Identification of a transcriptionally active hVH-5 pseudogene on 10q22.2. (2005) (8)
Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth* (2014) (8)
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. (2014) (8)
Identification of Elf-1 and B61 as high affinity ligands for the receptor tyrosine kinase MDK1 (1997) (8)
Protein kinase C: a new linkage marker for growth hormone and for COL1A1. (1989) (8)
Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants (2016) (7)
Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors. (2014) (7)
The structure of murine 7S nerve growth factor: implications for biosynthesis. (1985) (7)
Structural Relationships Between Growth Factor Precursors and Cell Surface Receptors (1986) (7)
The carboxy terminal 110 amino acid portion of the insulin receptor is important for insulin signalling to pyruvate dehydrogenase. (1992) (7)
Activation of insulin-epidermal growth factor (EGF) receptor chimerae regulates EGF receptor binding affinity (1992) (6)
Cell surface growth factor receptor molecules as targets for cancer therapy. (2004) (6)
The Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under Healthy Diet. (2018) (6)
Exclusive expression of the receptor tyrosine kinase MDK4 in skeletal muscle and the decidua (1996) (6)
Effects of Lithium Application Upon Extracellular Potassium Structures of the Peripheral and Central Nervous System of Rats (1981) (6)
The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen. (2003) (6)
Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach (2019) (6)
Nucleotide sequence of a human gene coding for a polypeptide hormone. (1977) (6)
Membrane bound receptor tyrosine kinases and chemical carcinogenesis. (1995) (5)
[Molecular portrait of human kidney carcinomas: the gene expression profiling of protein-tyrosine kinases and tyrosine phosphatases which controlled regulatory signals in the cells]. (2002) (5)
The cDNA Microarray Profiling of Protein Kinases and Phosphatases: Molecular Portrait of Human Prostate Carcinomas (2004) (5)
Nuclear and gene transplantation in the mouse. (1981) (5)
Localization of the gene for amiloride binding protein on chromosome 7 and RFLP analysis in cystic fibrosis families (1990) (5)
Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue (2017) (5)
Molecular Portrait of Human Kidney Carcinomas: The cDNA Microarray Profiling of Kinases and Phosphatases Involved in the Cell Signaling Control (2002) (4)
The novel protein-tyrosine phosphatase PTP20 is a positive regulator of PC12 cell neuronal differentiation. (2010) (4)
Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. (2001) (4)
Human Breast Cancer : Correlation of Relapse and Survival with Amplification of the HER-2 lneu Oncogene (2011) (4)
Protein kinase C. (1987) (4)
Antiphopholipid Antibodies and Functional Activated Protein C Resistance in Patients With Breast Cancer During Anthracycline-Based Chemotherapy Administered Through an Intravenous Port-Catheter Device (2014) (3)
Rescue of W-associated mast cell defects in W/Wv bone marrow cells by ectopic expression of normal and mutant epidermal growth factor receptors. (1993) (3)
Activation and regulation of the insulin receptor kinase. (1992) (3)
Changes of Extracellular Potassium in Rat Cerebellar Cortex Indicate a Reduced Na-K-Pump Activity during Acute and Chronic Li-Application (1981) (3)
Towards the prognostic significance and therapeutic potential of HER 3 receptor tyrosine kinase in human colon cancer (2011) (3)
Molecular characterization of a cDNA encoding functional human CLK4 kinase and localization to chromosome 5q35 [correction of 4q35]. (2001) (3)
THE HUMAN LEUKOCYTE INTERFERON GENE FAMILY: STRUCTURE AND EXPRESSION IN MAMMALIAN CELLS (1981) (2)
Functions of the erbA and erbB Oncogenes in Avian Erythroblatosis (1989) (2)
Rescue of W-associated mast cell defects in W/Wv bone marrow cells by ectopic expression of normal and mutant epidermal growth factor receptors (1993) (2)
Construction and expression of chimeric cell surface receptors. (1991) (2)
Single Nucleotide Polymorphisms in the G-Protein Coupled Receptor Kinase 5 (GRK5) Gene are associated with Plasma LDL-Cholesterol Levels in Humans (2018) (2)
Inhibition of Tumor Growth, Angiogenesis, and Microcirculation by the Novel Flk-1 Inhibitor SU5416 as Assessed by Intravital Multi-fluorescence Videomicroscopy 1 (1999) (2)
Use of Large Combinatorial Chemical Libraries for Anticancer Drug Discovery (1995) (2)
Synthetic peptide approach to the analysis of kinase activities of avian EGF receptor and v-erbB protein. (1985) (2)
Growth Factor Receptor ( TACE / ADAM 17 )-Mediated Transactivation of the Epidermal-Converting Enzyme α Necrosis Factor Cannabinoids Induce Cancer Cell Proliferation via Tumor (2004) (2)
Advances in Brief Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor-Converting Enzyme ( TACE / ADAM 17 )-Mediated Transactivation of the Epidermal Growth Factor Receptor (2004) (2)
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. (2006) (2)
Cancer as a communication disorder (2002) (2)
Development of Targeted Therapies in ErbB2-Positive Breast Cancer (2008) (1)
417: Visualization of tumor formation in the WAP-TGFa/FGFR4Arg385 KI breast cancer mouse model (2014) (1)
Identification of Antiapoptotic Protein Kinases and Phosphatases by a Functional Genomics Approach (2001) (1)
Use of DNA Polymorphisms to Establish the Linkage Map of the Pth, Beta-Globin, C-Ha-Ras-1, and Insulin Loci on 11p (1984) (1)
Growth factor receptors as targets for drug development (1995) (1)
Molecular Targets in Cancer Therapy and Their Impact on Cancer Management: 2nd State-of-the-Art Conference, Montreux, February 2002 (2002) (1)
Epidermal GrowthFactor (EGF)Stimulates Association andKinase Activity ofRaf-1 withtheEGF Receptor (1991) (1)
M 2 Induces Programmed Cell Death Nuclear Translocation of the Tumor Marker Pyruvate Kinase Updated (2007) (1)
Receptor Tyrosine Kinases as Targets for Cancer Therapy Development (2006) (1)
Negative Regulation of HER 2 Signaling by the PEST-type Protein-tyrosine Phosphatase BDP 1 * (2004) (1)
Epidermal Growth Factor Receptor Signal Trans-Activation (2003) (1)
Intermolecular transphosphorylation between insulin receptors and EGF-insulin receptor chimerae (1990) (1)
632: Tamoxifen resistance can be overcome by salinomycin treatment (2014) (1)
Structural and Functional Analysis of Cell Surface Receptors with Tyrosine Kinase Activity (1986) (1)
Expression of the hst-l and c-kit Protooncogenes in Human Testicular Germ Cell Tumors1 (2006) (1)
The structure and expression of the insulin gene (1978) (1)
Overexpression of Gas6 and Axl in prostate cancer (2008) (1)
SYNTHESIS OF HUMAN INTERFERONS AND ANALOGS IN HETEROLOGOUS CELLS (1982) (1)
Molecular cloning and sequence analysis of adult chicken betal globin cDNA. (1979) (1)
Forecast of ptp lar mediated diseases (2000) (0)
Use of proteinase inhibitors to prevent the splitting of growth factor precursors (2000) (0)
Toward the Prognostic Signi fi cance and Therapeutic Potential of HER 3 Receptor Tyrosine Kinase in Human Colon Cancer (2012) (0)
Table of Contents (1989) (0)
Foerfarande Foer framstaellning of a recombinant DNA-molecule to som innehaoller I Foer tillvaexthormon the encoding nukleotidsekvens, and which have kan anvaendas at framstaellning of a tillvaexthormon producerande Mikroorganismen (1981) (0)
8 – Structural basis of growth factor receptor mediated cellular signals (abstract) (1987) (0)
ActivationofInsulin-EpidermalGrowth Factor(EGF) Receptor Chimerae RegulatesEGF ReceptorBinding Affinity (1992) (0)
living cells. autophosphorylation of the EGF receptors in (EGF)-induced intermolecular Evidence for epidermal growth factor (2013) (0)
Cck-2, recepteur a tyrosine-kinase (1994) (0)
Table of Contents (1993) (0)
HumanHER2(neu) Promoter: Evidence forMultiple Mechanisms forTranscriptional Initiation (1987) (0)
Modulation of Ca2+-influx by the affinity of phospholipase C gamma to specific binding sites receptor tyrosine kinases (2007) (0)
Diagnostic et prevention de l'invasion des cellules cancereuses (2003) (0)
Inhibition of tumor growth by dominant negative inhibition of growth factor receptor signals. (1995) (0)
of Multiple Tumor Types Tyrosine Kinase Catalysis , Tumor Vascularization , and Growth Endothelial Growth Factor Receptor ( Flk-1 / KDR ) That Inhibits SU 5416 Is a Potent and Selective Inhibitor of the Vascular (1998) (0)
The avian f 3-adrenergic receptor : Primary structure and membrane topology ( adenylate cyclase / cDNA / rhodopsin / G protein ) (0)
Patents And literature (1985) (0)
From Genes to Cancer Therapies (2011) (0)
Induces Regression of Established Tumors SU 6668 Is a Potent Antiangiogenic and Antitumor Agent That Updated (2000) (0)
Use of inhibitors for the treatment of RTK over-function-related disorders, in particular cancer (1999) (0)
NOTES Retrovirus-Mediated Transfer ofan Adenovirus GeneEncoding an Integral MembraneProtein IsSufficient ToDownRegulate theReceptor forEpidermal GrowthFactor (1990) (0)
Dominant-negative inhibition of the receptor tyrosine kinase receptor AXL suppresses glioma cell migration and invasion and prolongs survival (2005) (0)
- CSF1R: CSF-1 receptor (vertebrates) (Macrophage-CSF receptor1, c-fms gene product2) (1995) (0)
Author index (1996) (0)
Human Preproinsulin: Primary Structure of the Messenger RNA (1980) (0)
Preparation of a composition against hepatitis b-, hi-, paramyxo- and orthomyxoviruses (1999) (0)
PTP-D protein tyrosine phosphatases subclass of (1993) (0)
1: Development of targeted cancer therapies (2014) (0)
Overexpression of Protein Kinase C α in Swiss/3T3 Cells Reduces The Number of Both High and Low Affinity of the Epidermal Growth Factor Receptors (1991) (0)
Dns-transfer-vector and a gen a higher organism containing microorganism (1978) (0)
Interference with cellular signal transduction mechanisms as basis for the development of novel cancer therapies (2007) (0)
Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer (2014) (0)
Improvements to growth factors. (1985) (0)
- InsR: Insulin receptor (vertebrates) (1995) (0)
A process for the cultivation of recombinant cells, host cell for use in the method and culture comprising the host cell (1988) (0)
A MutantEpidermal GrowthFactor Receptor withDefective Protein Tyrosine Kinase IsUnable ToStimulate Proto-Oncogene Expression andDNA Synthesis (1987) (0)
EPIDERMAL GROWTH FACTOR mRNA CODES FOR A POTENTIAL POLYPROTEIN PRECURSOR (1983) (0)
Regulation of immunostimulating tumor-associated antigen-90K in ovarian cancer cells (1994) (0)
Modulation of pl 45 c " kit Function in Cells of Patients with Acute Myeloblastic Leukemia 1 (2006) (0)
Isolation and Characterization of DNA Sequences Coding for Mouse and Human β-Nerve Growth Factor (1984) (0)
Evidence forEpidermal GrowthFactor (EGF)-Induced Intermolecular Autophosphorylation oftheEGF Receptors inLiving Cells (1990) (0)
in Vivo of Many Tumor Types Dominant-Negative Inhibition of Flk-1 Suppresses the Growth Updated Version (2006) (0)
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis (2012) (0)
OTTO WARBURG-LECTURE: Onco Genome Analysis Towards Strategies for the Development of Novel Cancer Drugs: From Target-Specific to Multi-Targeted Therapies (2005) (0)
Growth factor receptor mediated signal transduction (1990) (0)
Use of inhibitors of the platelet-fragments of muscles growth factor receptor for the manufacture of a lægmiddel to Behan (1995) (0)
Human Tumors and the Epidermal Growth Factor Receptor by β and α Factors Synthesis of Messenger RNAs for Transforming Growth (2006) (0)
Factor Receptor Signal Transactivation Cell Proliferation and Motility Involves Epidermal Growth Lysophosphatidic Acid-induced Squamous Cell Carcinoma (2002) (0)
Transplantation of the human insulin gene into fertilized mouse eggs. (1982) (0)
Molecular Features Involved in Cell Surface Receptor Function and Their Role in Oncogenesis (1987) (0)
A recombinant DNA transfer vector (1991) (0)
Combined inhibition of VEGF and PDGF signalling: Effects on orthotopic glioma angiogenesis, microcirculation, and growth (2005) (0)
Procedure for the cultivation of recombinant cells, host cell for use in the method and the host cell culture comprising (1988) (0)
Use of inhibitors of the receptor of platelet-derived growth factors for preparing a medicament for the treatment of cancer (1995) (0)
791: Investigation of the mode of action of sunitinib kinase inhibitor profile analogues in insulin release (2014) (0)
RolesofInsulinlike GrowthFactor 1(IGF-1) andtheIGF-1 Receptor inEpidermal GrowthFactor-Stimulated Growthof3T3Cells (1992) (0)
Mutual regulation of protein-tyrosine phosphatase 20 and protein-tyrosine kinase Tec activities by tyrosine phosphorylation and dephosphorylation. (2010) (0)
DNA transfer vector and recombinant microorganism containing a gene from a higher organism (1978) (0)
O-40: Phosphotyrosine phosphatase 1D mediates insulin-induced tyrosine dephosphorylation of focal adhesion kinase and rearrangement of the actin cytoskeleton (2009) (0)
, Karl tuberculosis Mycobacterium Tyrosine Phosphatases of Cloning and Characterization of Secretory (2000) (0)
Diagnosis and prevention of the invasion of cancer cells. (2003) (0)
Monoclonal antibody against c-kit (1992) (0)
Preparation of human nerve growth factor by genetic recombination (1992) (0)
CCK-2 receptor tyrosine kinase one (1994) (0)
SIGNAL TRANSDUCTION THERAPY OF TUMORS WITH MULTIPLE TARGET KINASE INHIBITORS (2008) (0)
Current Signal Transduction Therapy: Preface (2011) (0)
The receptor tyrosine kinase Axl is widely expressed in gliomas of various histology (2006) (0)
Erratum: Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation (2006) (0)
Everything you wanted to know about cytokines, but were afraid to ask (1996) (0)
Anti-angiogene Gentherapie mittels eines dominant negativen VEGF-R2 kodierendem Retroviruses (2001) (0)
Structure and expression in bacteria of growth hormone genes (1979) (0)
Dominant-negative membrane-bound Flk-1 receptor of the vascular endothelial growth factor VEGF (1993) (0)
Mutational Analysis of the EGF Receptor Proto-Oncogene (1989) (0)
ErbB2: EGF-receptor related PTK (vertebrates) (c-neu, HER2) (1995) (0)
222 POSTER RNAi screen for Akt regulator (2008) (0)
403 Regulation of matrix metalloproteinase 3 by tumor-associated mutant E-cadherin variants (2004) (0)
epidermal growth factor. sufficient to down regulate the receptor for is gene encoding an integral membrane protein Retrovirus-mediated transfer of an adenovirus (2013) (0)
A medicament useful for the mutated growth factor receptor and its use in the treatment of cancer (1994) (0)
Linkage Analysis in Familial Dysautonomia Using Variations in DNA Sequence in the β-Nerve Growth Factor Gene Region: A Beginning (1984) (0)
Activation of HER 3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors : Suggestion of Combination Therapy 1 (2014) (0)
Table of Contents (1990) (0)
Preparation of human nerve growth factor by recombinant technology (1992) (0)
Table of Contents (1994) (0)
Protein Kinase C: Structural Definition (2020) (0)
Target-specific anti-angiogenic cancer therapy (2001) (0)
361 POSTER FGFR4 Y367C: Contributes to a constitutively active FGFR4 and tumour aggressiveness in breast cancer cell line (2008) (0)
Further Studies of the Signaling Mechanisms of the Antitumor Somatostatin Analogue TT-232 (2001) (0)
A method for determining the activity of Phosphotyrosinphosphatasen and for identifying effectors thereof (1994) (0)
extracellular domain of HER2. (1990) (0)
68 Targeted Cancer Therapy Development (2012) (0)
Molecular Cloning andExpression ofa G25KcDNA,theHuman HomologoftheYeastCellCycleGeneCDC42 (1990) (0)
Culture of recombinant cell (1988) (0)
DNA transfer vector for transformation of a microorganism (1978) (0)
789: Combinatorial treatment of lung cancer cell lines and their spheroids-cancer stem cells with standard therapeutic drug and salinomycin (2014) (0)
A process for the production of mature human insulin-like growth factor (IGF-I), or a human IGF-I-fusion protein, exp (1984) (0)
M 1 – 004 Receptor tyrosine kinase inhibition in cancer therapy : from monospecific to multi-targeted drugs (2005) (0)
228 INVITED From Genes to Cancer Therapies (2011) (0)
Drug Discovery and Development in the Kinase Inhibitory Field with Nested Chemical Library TM (2007) (0)
Epidermal growth factor receptor (EGFR) in mammary-carcinoma metastasis (1991) (0)
Fibroblast growth factor receptor 4 regulates proliferation , anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention q (2018) (0)
446: A gain of function by the cancer-associated FGFR4 c.1162G>A (p.Gly388Arg) variant (2014) (0)
- EGFR: EGF receptor (vertebrates) (c-erbB) (1995) (0)
Antibody-mediated depletion of protein variant expression in living cells (Protein interference) (2017) (0)
Expression of c-kit Receptor in Normal and Transformed Human Nonlymphoid Tissues1 (2006) (0)
IGF1R: IGF1 receptor (vertebrates) (Somatomedin receptor) (1995) (0)
Epidermal Growth Factor Receptor Autophosphorylation Is Not Required for Normal Mitogenic or Transforming Signal Generation (1991) (0)
Signal transduction therapy of colon tumors with multiple target kinase inhibitors (2009) (0)
Table of Contents (1984) (0)
PTP-Meg2 - A New Functional Player During Early Retinogenesis? (2012) (0)
Protein kinase C--structural studies. (1988) (0)
Detection of ERK1/2 activities using affinity reagents. (2004) (0)
An insertional mutant of epidermal growth factor receptor allows dissection of diverse receptor functions. (1987) (0)
Structure of a minimal Gas6-Axl complex (2005) (0)
Spbfamilia ptp-protein tyrosine phosphatases d. (1993) (0)
GROVV"TH FACTOR RECEPTOR TYRO'SINE KINASES (1988) (0)
Exploring the involvement of FGFR4 in hepatocellular carcinoma (2007) (0)
Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines (2015) (0)
Contents, Vol. 34, Supplement 1, 1994 (1994) (0)
Release ofaPhorbol Ester-Induced Mitogenic BlockbyMutation at Thr-654 oftheEpidermal GrowthFactor Receptor (1988) (0)
The use of inhibitors for the treatment of hyper-RTK function-related disorders, in particular cancer (1999) (0)
Table of Contents (1996) (0)
A polypeptide having the properties of human beta-nerve growth factor and process for their preparation, DNA isolate comprising a sequence encoding the polypeptide, replicable expression vector for the DNA sequence, recombinant host cell transformed with the vector, pharmaceutical composition contai (1984) (0)
METHODS USEFUL IN MODULATING PROTEIN TYROSINE PHOSPHATASES (2017) (0)
Use of a modulating agent acting on a precursor of growth factor in order to inhibit the treatment of growth factor precursor. (2000) (0)
801: Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors − suggestion of combination therapy (2014) (0)
Visualization of breast cancer progression with PET using the WAP-TGF{alpha};FGFR4 mouse model (2014) (0)
DNA-dependent protein synthesis exhibited by cancer shed particulates (2017) (0)
C-terminal LG domain pair of human Gas6 (2003) (0)
Chicken Epidermal GrowthFactor (EGF)Receptor: cDNACloning, Expression inMouseCells, andDifferential Binding ofEGFand Transforming GrowthFactor Alpha (1988) (0)
EphB4 signaling regulates vascular morphogenesis and permeability in adult neo-angiogenesis, both under pathological and physiological conditions (2004) (0)
Preparation of human nerve growth factor by gene recombinant (1992) (0)
and RecyclingofEGF ReceptorMutants (1992) (0)
Processes for the production of recombinant cells. (1988) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Axel Prof. Dr. Ullrich?

Axel Prof. Dr. Ullrich is affiliated with the following schools:

Axel Prof. Dr. Ullrich's Academic­Influence.com Rankings

Axel Prof. Dr. Ullrich's Degrees

Similar Degrees You Can Earn

Why Is Axel Prof. Dr. Ullrich Influential?

Axel Prof. Dr. Ullrich's Published Works

Published Works

What Schools Are Affiliated With Axel Prof. Dr. Ullrich?

Axel Prof. Dr. Ullrich's AcademicInfluence.com Rankings